Empagliflozin patent expiry?

What is the Empagliflozin patent expiry date?

Empagliflozin, sold under the brand name Jardiance among others, is an oral anti-diabetic medication used to treat type 2 diabetes and in certain cases, heart failure [1]. It is jointly developed and marketed by Boehringer Ingelheim and Eli Lilly and Company.

According to the patent database on DrugPatentWatch.com [2], the patents for Empagliflozin are set to expire in 2027. The patents are owned by various companies, including Boehringer Ingelheim, Eli Lilly and Company, and Merck & Co [3].

How will the expiry of the patent affect patients and healthcare providers?

The expiry of the Empagliflozin patent may lead to the entry of generic versions of the medication, which can increase competition and reduce prices [4]. This can make the medication more accessible to patients who may not have previously been able to afford it. However, the exact impact on prices and availability will depend on factors such as the number of generic manufacturers and the level of competition in the market.

Who makes generic versions of Empagliflozin?

Several companies have filed for approval to manufacture generic versions of Empagliflozin in various countries around the world [5]. These companies include Mylan, Teva Pharmaceutical Industries, and Sun Pharmaceutical Industries, among others. However, not all generic versions may be approved, and the actual number of generic manufacturers will depend on factors such as regulatoryapproval and market demand.

When can patients expect to see generic versions of Empagliflozin?

The exact timing of the availability of generic versions of Empagliflozin will depend on various factors, including the pace of regulatory approval and market demand [6]. In general, generic versions of a medication tend to become widely available within 12-18 months after the patent expiry.

What happens when the patent expires?

When the patent expires, the medication enters the public domain, and manufacturers who have obtained regulatory approval can start marketing their version of the medication [7]. This can lead to a significant increase in competition, which can drive down prices and increase availability.

References:

[1] https://en.wikipedia.org/wiki/Empagliflozin

[2] https://www.drugpatentwatch.com/DrugPatents/14292-DrugPatent

[3] https://www.drugpatentwatch.com/DrugPatents/14292-DrugPatent

[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461245/

[5] https://www.drugpatentwatch.com/Generics/13695-Generic

[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494346/

[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451119/